GDLP JD - PYC Therapeutics CEO Director
| PYC Stock | 1.40 0.05 3.45% |
CEO
GDLP JD is CEO Director of PYC Therapeutics
| Age | 40 |
| Address | Harry Perkins Inst. of Medical Research, Nedlands, WA, Australia, 6009 |
| Phone | 61 8 6151 0992 |
| Web | https://pyctx.com |
PYC Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.3783) % which means that it has lost $0.3783 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.6961) %, meaning that it generated substantial loss on money invested by shareholders. PYC Therapeutics' management efficiency ratios could be used to measure how well PYC Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Total Current Liabilities is likely to gain to about 9.6 M in 2024. Liabilities And Stockholders Equity is likely to gain to about 95.8 M in 2024Similar Executives
| Found 3 records | CEO Age | ||
| Matthew Wilson | Light Wonder | 42 | |
| MD MBBS | Pro Medicus | N/A | |
| BCom ACA | Rea Group | 60 | |
Management Performance
| Return On Equity | -0.7 | ||||
| Return On Asset | -0.38 |
PYC Therapeutics Leadership Team
Elected by the shareholders, the PYC Therapeutics' board of directors comprises two types of representatives: PYC Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of PYC. The board's role is to monitor PYC Therapeutics' management team and ensure that shareholders' interests are well served. PYC Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, PYC Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| MD MBA, Chief Operations | ||
| Glenn Noronha, Chief Officer | ||
| BComm BCom, Company Secretary | ||
| Pr Fletcher, Chief Officer | ||
| GDLP JD, CEO Director |
PYC Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is PYC Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.7 | ||||
| Return On Asset | -0.38 | ||||
| Profit Margin | (1.71) % | ||||
| Operating Margin | (1.78) % | ||||
| Current Valuation | 587.49 M | ||||
| Shares Outstanding | 466.61 M | ||||
| Shares Owned By Insiders | 59.23 % | ||||
| Shares Owned By Institutions | 0.57 % | ||||
| Price To Book | 8.12 X | ||||
| Price To Sales | 29.61 X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for PYC Stock Analysis
When running PYC Therapeutics' price analysis, check to measure PYC Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy PYC Therapeutics is operating at the current time. Most of PYC Therapeutics' value examination focuses on studying past and present price action to predict the probability of PYC Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move PYC Therapeutics' price. Additionally, you may evaluate how the addition of PYC Therapeutics to your portfolios can decrease your overall portfolio volatility.